The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006-Reference-Cited by-同舟云学术

The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006

Published:2011-08-08 Issue:1 Volume:21 Page:49-52
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Herrinton Lisa J.¹,Liu Liyan¹,Abramson Oren²,Jaffe Elaine S.³

Affiliation:

1. Division of Research; Kaiser Permanente Northern California; Oakland CA USA

2. Department of Pediatric Gastroenterology; Kaiser Permanente Northern California; Oakland CA USA

3. Hematopathology Section, Laboratory of Pathology; Center for Cancer Research; National Cancer Institute; Bethesda MD USA

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.2216/fullpdf

Reference14 articles.

1. cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990;Weidmann;Leukemia,2000

2. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients;Belhadj;Blood,2003

3. Hepatosplenic gammadelta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q;Francois;Am J Surg Pathol,1997

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignancy, a real risk in patients using anti-TNF drugs for Crohn’s disease?;Journal of Case Reports and Images in Pathology;2024-08-29

2. Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders;Lymphoma;2021-12-27

3. 18F-fluorodeoxyglucose positron emission tomography—based prediction for splenectomy in patients with suspected splenic lymphoma;Annals of Translational Medicine;2021-06

4. Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders;Current Drug Safety;2017-07-10

5. Incidence, clinical findings, and survival of hepatosplenic T-cell lymphoma in the United States;American Journal of Hematology;2017-04-29